Pregnant women should be aware that Adcetris might cause harm to their unborn baby.
妊娠妇女应认识到Adcetris可能致她们的未生产孩子危害。
The effectiveness of Adcetris in patients with HL was evaluated in a single clinical trial involving 102 patients.
在一项单个临床试验涉及102例患者中评价HL患者中Adcetris的有效性。
Adcetris may also be used in patients with ALCL whose disease has progressed after one prior chemotherapy treatment.
Adcetris还可用于1次既往化疗后疾病进展的ALCL患者。
The effectiveness of Adcetris in patients with systemic ALCL was evaluated in a single clinical trial in 58 patients.
在一项单次临床试验中在58例患者中评价Adcetris在全身ALCL患者中的有效性。
Of the patients receiving Adcetris for ALCL, 86 percent experienced either a complete or partial response and responded on average for 12.6 months.
为ALCL接受Adcetris患者中，86%经受或完全或部分缓解和平均缓解12.6个月。
Adcetris is an antibody-drug conjugate that combines an antibody and drug, allowing the antibody to direct the drug to a target on lymphoma cells known as CD30.
Adcetris是一种抗体药物结合物， 结合抗体和药物，允许抗体指引药物至淋巴瘤细胞上被称为D30靶点。
Adcetris is to be used in patients with HL whose disease has progressed after autologous stem cell transplant or after two prior chemotherapy treatments for those who cannot receive a transplant.
Adcetris被用于自身干细胞移植后或两次既往化疗后疾病有进展不能接受移植HL患者。
Adcetris is to be used in patients with HL whose disease has progressed after autologous stem cell transplant or after two prior chemotherapy treatments for those who cannot receive a transplant.
Adcetris被用于自身干细胞移植后或两次既往化疗后疾病有进展不能接受移植HL患者。
应用推荐